ANCA相关性巩膜炎:ANCA对临床表现、治疗反应及结局的影响
这项回顾性多中心病例对照研究比较了38例孤立性ANCA相关性巩膜炎与82例ANCA阴性特发性巩膜炎,发现ANCA阳性者巩膜软化更常见、更需全身糖皮质激素和利妥昔单抗、缓解率更低,30.7%的PR3-或MPO-ANCA患者在中位30个月后进展为系统性ANCA相关性血管炎。
要点
- ANCA相关性巩膜炎巩膜软化较ANCA阴性特发性巩膜炎更常见(P=0.027)。
- ANCA相关性巩膜炎更常需全身糖皮质激素(76% vs 34%;P<0.001)和利妥昔单抗(P=0.03),一线及二线治疗后缓解率更低。
- 诊断时CRP>5 mg/l是进展为系统性ANCA相关性血管炎的唯一显著危险因素,校正风险比5.85(95%CI 1.10, 31.01),P=0.038。
核心结论
- 孤立性ANCA相关性巩膜炎多为前巩膜炎,较ANCA阴性特发性巩膜炎巩膜软化风险更高,且更常难以治疗。
- PR3-或MPO-ANCA巩膜炎患者中三分之一进展为系统性ANCA相关性血管炎。
研究设计与样本
- 法国血管炎研究组(FVSG)网络及三家法国三级眼科中心开展的回顾性多中心病例对照研究。
- 纳入2007年1月至2022年4月诊断的120例患者,包括38例无全身表现且ANCA阳性的巩膜炎患者和82例ANCA阴性特发性巩膜炎对照。
- 中位随访28个月(IQR 10-60),诊断时中位年龄48岁(IQR 33-60),女性占75%。
主要发现
- ANCA阳性患者巩膜软化更常见(P=0.027),54%伴有相关眼科表现,组间无显著差异。
- ANCA相关性巩膜炎更常需全身用药,包括糖皮质激素(76% vs 34%;P<0.001)和利妥昔单抗(P=0.03)。
- ANCA相关性巩膜炎一线及二线治疗后缓解率更低。
- PR3-或MPO-ANCA巩膜炎患者中30.7%发生系统性ANCA相关性血管炎,中位间隔30个月(IQR 16.3-44)。
- 诊断时CRP>5 mg/l是进展为系统性ANCA相关性血管炎的唯一显著危险因素,校正风险比5.85(95%CI 1.10, 31.01),P=0.038。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To describe the characteristics, treatment and outcome of isolated ANCA-associated scleritis at diagnosis compared with idiopathic scleritis with negative ANCA tests. METHODS: This retrospective multicentre case-control study was performed within the French Vasculitis Study Group (FVSG) network and in three French tertiary ophthalmologic centres. Data from patients with scleritis without any systemic manifestation and with positive ANCA results were compared with those of a control group of patients with idiopathic scleritis with negative ANCA tests. RESULTS: A total of 120 patients, including 38 patients with ANCA-associated scleritis and 82 control patients, diagnosed between January 2007 and April 2022 were included. The median follow-up was 28 months (IQR 10-60). The median age at diagnosis was 48 years (IQR 33-60) and 75% were females. Scleromalacia was more frequent in ANCA-positive patients (P = 0.027) and 54% had associated ophthalmologic manifestations, without significant differences. ANCA-associated scleritis more frequently required systemic medications, including glucocorticoids (76% vs 34%; P < 0.001), and rituximab (P = 0.03) and had a lower remission rate after the first- and second-line treatment. Systemic ANCA-associated vasculitis (AAV) occurred in 30.7% of patients with PR3- or MPO-ANCA, after a median interval of 30 months (IQR 16.3-44). Increased CRP >5 mg/l at diagnosis was the only significant risk factor of progression to systemic AAV [adjusted hazard ratio 5.85 (95% CI 1.10, 31.01), P = 0.038]. CONCLUSION: Isolated ANCA-associated scleritis is mostly anterior scleritis with a higher risk of scleromalacia than ANCA-negative idiopathic scleritis and is more often difficult to treat. One-third of patients with PR3- or MPO-ANCA scleritis progressed to systemic AAV.
引用
- Perray L, Nguyen Y, Clavel Refregiers G, et al. ANCA-associated scleritis: impact of ANCA on presentation, response to therapy and outcome. Rheumatology (Oxford). 2024. PMID: 37233203. doi:10.1093/rheumatology/kead252
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。